| Study name |
Levetiracetam for Alzheimer's Disease‐Associated Network Hyperexcitability |
| Methods |
Randomized cross‐over assignment |
| Participants |
Meets National Institute on Aging‐Alzheimer's Association Workgroups criteria for probable AD dementia; age ≤ 80 years at time of screening; willing and able caregiver who has daily contact with the subject; MMSE score ≥ 18 and/or CDR < 2 at the initial screening assessment |
| Interventions |
Levetiracetam and placebo |
| Outcomes |
Changes in executive function, epileptiform activity frequency, cognitive function and behavior and level of disability |
| Starting date |
January 2018 |
| Contact information |
Keith A Vossel, MD, MSc. University of Minnesota ‐ Clinical and Translational Science Institute |
| Notes |
Estimated study completion date: December 2019 |
